Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ESMO 2021 | TULIP: trastuzumab duocarmazine improved PFS in pre-treated HER2+ breast cancer

Cristina Saura Manich • 29 Sep 2021

ESMO 2021

Breast Cancer Antibodies Trastuzumab duocarmazine

TULIP

Cristina Saura Manich, MD, PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, presents results from the TULIP study, a Phase III trial comparing trastuzumab duocarmazine to physicians choice treatment in patients with pre-treated HER2-positive, locally advanced or metastatic breast cancer. In this trial, treatment with trastuzumab duocarmazine significantly improved progression-free survival in comparison to physians choice. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.